San Francisco - Alefacept (Amevive) offers efficacy for a broad spectrum of patients with chronic plaque psoriasis who are considered candidates for systemic therapy or phototherapy, according to the results of a retrospective study.
Insights into Bimekizumab 2-Year Data for PsA, nr-asSpA, and AS
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Deep Histological Margins Do Not Increase cSCC Recurrence Risk if Tumor is Fully Excised
The Cutaneous Connection: Enhancing Vitiligo Care With Nanette Silverberg, MD
Latex Gloves and the Americans With Disabilities Act
Comprehensive Review of the Nitra Practice Expense Card 2024: Essential for Healthcare Providers?